Related Experiment Video
Updated: Aug 16, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells
1Wihuri Research Institute, Kalliolinnatie 4, Helsinki, 00140, Finland.
Insights
Proteases in the arterial intima, like plasmin and plasma kallikrein, reduce high-density lipoprotein
Area of Science:
- Cardiovascular Biology
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Arterial intima contains proteases that may affect high-density lipoprotein (HDL) function.
- Impaired HDL cholesterol acceptance is linked to cardiovascular disease.
Purpose of the Study:
- To investigate the impact of arterial intima proteases (plasmin, plasma kallikrein) on HDL's cholesterol efflux capacity.
- To understand the mechanism by which proteases affect HDL functionality.
Main Methods:
- Human HDL(3) was treated with human plasmin and plasma kallikrein.
- Cholesterol efflux from macrophage foam cells was measured.
- Proteolytic degradation products of HDL(3) were analyzed using SDS-PAGE and agarose gel electrophoresis.
Main Results:
- Exposure to plasmin or plasma kallikrein reduced HDL(3)'s cholesterol efflux capacity by approximately 60%.
- Protease treatment generated smaller cleavage products and led to the loss of HDL(3) with prebeta-mobility.
- Apolipoprotein integrity was largely maintained, suggesting degradation of a subpopulation of HDL particles.
Conclusions:
- Plasmin and plasma kallikrein in the arterial intima can impair HDL's ability to remove cholesterol from macrophages.
- This impaired cholesterol efflux may contribute to the development of atherosclerosis.
Abstract:
Arterial intima contains metabolically active factors such as proteases, which may act on high-density lipoprotein (HDL) and impair its ability to accept cholesterol. In this study we treated human HDL(3) with human plasmin and human plasma kallikrein, two proteases also found in the human arterial intima, in order to study their effect on the ability of HDL(3) to promote cholesterol efflux from human macrophage foam cells. After exposure to plasmin or plasma kallikrein for 15 min, HDL(3) showed a decrease of about 60% in its ability to promote cholesterol efflux from the macrophage foam cells. SDS-PAGE analysis of the degraded HDL(3) particles showed that plasmin had generated cleavage products less than 15 kDa in size and plasma kallikrein had generated a major product of about 19 kDa. However, there was only a slight loss of intact apolipoproteins, suggesting degradation of a small subpopulation of HDL(3) particles. Agarose gel electrophoresis showed that a decrease in cholesterol efflux was accompanied by total loss of the HDL(3) with prebeta-mobility, but no apparent change in those with alpha mobility. These results suggest that the presence of active plasmin or plasma kallikrein in the atherosclerotic arterial intima promotes atherogenesis by blocking cholesterol efflux from macrophage foam cells.
Related Concept Videos
Inflammation
Cytoskeletal Linker Proteins - Plakins
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Clot Retraction and Fibrinolysis
Cholesterol: Significance and Regulation
Considering cholesterol and...

